200
Participants
Start Date
January 14, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Zanidatamab
Administered by intravenous (IV) infusion
RECRUITING
Seoul National University Bundang Hospital, Seoul
RECRUITING
Alliance Cancer Specialists, Horsham
RECRUITING
Blue Ridge Cancer Care, Roanoke
RECRUITING
Florida Cancer Specialists - Lake Nona, Orlando
RECRUITING
Florida Cancer Specialists - East, West Palm Beach
RECRUITING
Florida Cancer Specialists - North, St. Petersburg
RECRUITING
Florida Cancer Specialists - South, Fort Myers
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Tennessee Cancer Specialists, Knoxville
RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
RECRUITING
Affiliated Oncologists, Chicago Ridge
RECRUITING
Texas Oncology - DFW, Dallas
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Texas Oncology - San Antonio, San Antonio
RECRUITING
Texas Oncology - West Texas, Amarillo
RECRUITING
Rocky Mountain Cancer Center, Littleton
RECRUITING
Arizona Oncology Associates, PC - NAHOA, Prescott
RECRUITING
Samsung Medical Center, Gangnam-gu
RECRUITING
Seoul National University Hospital, Jongno-gu
RECRUITING
Severance Hospital, Seodaemun-gu
RECRUITING
Asan Medical Center, Seoul
Lead Sponsor
Collaborators (1)
Jazz Pharmaceuticals Ireland Limited
INDUSTRY
Jazz Pharmaceuticals
INDUSTRY